The HairMax LaserComb is the first FDA Cleared tool that utilizes laser phototherapy to efficiently support hair development and treat hair loss in both men & women. Laser light is directly applied to the hair follicles, infusing them with the energy needed to excite growth factors, increase the growth phase, and help reestablish a healthy hair growth cycle. The LaserComb produces visible light in the red spectrum, which has been clinically proven to successfully treat hair loss and stimulate the hair follicles, resulting in hair growth. All living cells "like" light and your hair is no different. The most common example of light converting into chemical energy is photosynthesis, where plants are fed via light converted into chemical energy. Scientific studies on cell cultures have shown that laser penetrates into soft tissue and increases the action of adenosine triphosphate (ATP), a molecule that is a major carrier of energy from one reaction site to another in all living cells. Individual cells increase their activity level due to ATP. ATP plays an essential role in the cell as an energy transporter. In addition, the laser light therapy from the comb increases blood flow to the scalp, therefore, increasing circulation in the scalp, which helps with elimination of DHT.
The HairMax LaserComb also has a patented hair-parting mechanism allowing light to reach the scalp. Because of this feature, hair follicles reap the full benefits of phototherapy. The three cycles of hair growth are the anagen (growth phase), catogen (transition phase), and telogen (resting phase) phases. During the catogen and telogen phases, the LaserComb stimulates the hair follicles, which leads to shedding and promotes the growth of new hairs (anagen phase). For this reason, many people will experience increased shedding upon initial use of the product. However, this should indicate the HairMax LaserComb is in fact working, and one should not be worried. The shedding should subside. In one recent study published January 2014 in the American Journal of Clinical Dermatology, the lasercomb was shown to be statistically significant compared to sham treatment at increasing terminal hair density by week 26. The improvements in hair density were independent of sex, age, and lasercomb model, as long as the same laser dose was administered. The increase found in terminal hair count is similar to short-term studies done with minoxidil 5% topical solution or finasteride 1mg per day; however, the efficacy of the lasercomb is not as good as these drugs have shown in longer studies (at least one year or longer). More studies are needed to determine optimal duration of treatment and response as well as other types of hair loss conditions the lasercomb may treat.